SCHIZOPHRENIA DRUG
-
Neurocrine halts development of schizophrenia drug as trial fails
The company said the drug, luvadaxistat, did not replicate the results from a previous mid-stage trial that showed improved cognitive performance, due to a large variability in the cognitive measures across the patients and a potential imbalance in their baseline characteristics.
-
Indivior shares dive on profit warning, dropping of schizophrenia drug
-
Teva, Medincell's schizophrenia drug succeeds in late-stage study
-
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
-
Vanda Pharmaceuticals sues US government over drug trade secrets
-
Karuna shares jump as schizophrenia drug meets goal in late-stage trial
-
Lupin gets USFDA nod for generic schizophrenia drug
Join the community of 2M+ industry professionals
Subscribe to our Daily Newsletter
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
